SUMMARY Patients suffering from chronic duodenal ulceration were allocated at random to treatment with either cimetidine (400 mg twice daily) or matching placebo for six months. Before entry to the trial all patients were shown to have healed ulcers on endoscopy. Most of the patients had participated in a one-month trial of cimetidine during which their ulcers healed. The trial showed that four of 29 patients relapsed on maintenance treatment with cimetidine, which therefore did not confer complete immunity from relapse. However, cimetidine treatment was very much better than placebo treatment, on which 18 of 31 patients relapsed. Of the 22 patients who relapsed clinically, 20 were submitted to endoscopy and 19 of these were shown to have ulcerated again. Endoscopy at the end of the trial showed that ulcers had also redeveloped in five of 28 asymptomatic patients. Length of previous dyspeptic history had no bearing on the results of the trial but there was evidence that relapse on placebo was less likely if the ulcer had originally healed on a high dose of cimetidine. Clinical relapse was associated with worsening duodenitis. Symptoms, clinical observation, and laboratory tests showed no important abnormalities in the patients.
cimetidine, in doses of 0.8-2.0 g/day produces a significantly higher incidence of healing than does placebo treatment, the healing rate on cimetidine being 70-80% in most series (see, for example, Bodemar and Walan, 1976; Blackwood et al., 1976; Gray et al., 1977; Multicentre Trial, 1979) .
We present an investigation of the effectiveness of cimetidine in maintaining symptomatic and endoscopic remission of chronic duodenal ulceration. The trial was begun in the latter part of 1976 and was completed about a year later. In the interval, others have published results of similar trials which also show the value of maintenance treatment with 'Address for correspondence: J. H. Wyllie, University College Hospital, London WC1.
Received for publication 14 September 1978 cimetidine (Bardhan et al., 1977; Bodemar and Walan, 1978; Gray et al., 1978; Hetzel et al., 1978) .
Methods

PATIENTS
Outpatients who fulfilled the following criteria entered the trial. Complete ulcer healing (with or without resolution of duodenitis) was shown by endoscopynot more than48 hours after stoppingtreatment with cimetidine 1 or 2 g/day or (in a few cases) matching placebo. Most patients had received this treatment over a four week period within a multicentre study of the effect of cimetidine on the healing of duodenal ulcers (Multicentre Trial, 1979) and for these the series was essentially consecutive, apart from the exclusion of patients known to have other gastrointestinal disease, or who had undergone ulcer surgery other than simple suture of a perforation. Pregnant and lactating women, and children under 16 years of age, were also excluded. All patients were in 158 Double-blind comparison of cimetidine andplacebo in the maintenance of healing symptomatic remission and each gave his informed consent to the trial, which had the approval of local ethics committees.
Patients were randomly allocated to receive either cimetidine 400 mg (two tablets) in the morning and at bedtime, or matching placebo. No other treatment was allowed except a standard antacid (unmarked Rennie tablets), which could be taken as frequently as required for the relief of ulcer pain which was not controlled by the trial medication. Each patient was provided with a diary card, on which was recorded antacid consumption and diurnal and nocturnal ulcer pain. Patients were seen every fortnight for the first eight weeks and then monthly for up to six months, the duration of the study. At each attendance the diary cards were inspected and unexpected or untoward symptoms were recorded, and blood was taken for a full blood count, platelet count, reticulocyte count, and estimation of plasma or serum transaminases, bilirubin, alkaline phosphatase, creatinine, urea, and urate. The urine was also tested for protein and sugar. Counts of returned tablets were not made but the patients were asked whether they had missed any doses. Endoscopic examination was performed before the trial and at the end of treatment, or when the clinician considered that symptomatic relapse had occurred. The patients who were re-endoscoped provide strong evidence that cimetidine prevented reulceration (X2 = 12X19, p < 0'001), but this cannot be accepted as absolute proof because we do not know whether or not re-ulceration occurred in the 12 patients who declined the final endoscopy. We can say, however, that, when relapse occurred, the chance of finding ulceration on endoscopy was 17/17 for patients on placebo and 2/3 for patients on cimetidine. And when the patients remained well the chance of finding ulceration on endoscopy was 3/10 for patients on placebo and 2/16 for patients on cimetidine. There is therefore no reason to suspect asymptomatic patients on cimetidine of being more liable to ulceration than asymptomatic patients on placebo-rather the reverse-and so it seems unreasonable to doubt that cimetidine promoted ulcer healing. Even if we assume the worst possible result for patients who were not re-endoscoped and imagine that none of those on placebo developed ulcers and that all of those on cimetidine did so, the Table 2 shows, for patients on cimetidine and placebo, that the length of previous dyspeptic history had no obvious bearing on the results of maintenance treatment with either placebo or cimetidine. In contrast, the dose of cimetidine used to heal ulcers immediately before this maintenance trial may have had a bearing on the results. Table 3 shows for 53 patients the numbers relapsing on placebo or Improvement in duodenitis scores was associated with the patients remaining well (X21 = 7.90, P < 0-02) but the corresponding test whether duodenitis scores were associated with cimetidine therapy failed to reach significance (X,2 = 3.09).
These mean scores were obtained by taking, for each patient in a group, the sum of scores for severity and extent of duodenitis (these being usually the same). The sums of the scores were added together and divided by the number of patients in each group. Double-blind comparison of cimetidine and placebo in the maintenance of healing In the Figure the stepwise fall in the number of patients remaining in clinical remission shows, in the case of those on placebo, a remorseless downward trend over six months. Cimetidine treatment was effective in preventing this but did not confer complete immunity. Moreover, endoscopy at the end of six months discovered a total of five unsuspected ulcers (two in the cimetidine group and three in the placebo group) as indicated by the asterisks. Thus, although cimetidine was clearly superior to placebo, reulceration occurred in at least 21 % of patients treated for six months with 800 mg/day.
Untoward symptoms unrelated to ulcer disease were reported by 14 patients (seven on cimetidine, seven on placebo); none of these symptoms required the patient's withdrawal from the trial. No symptom occurred consistently in either treatment group, as shown in Table 5 . There were no withdrawals from the study because of abnormal laboratory results. Abnormal biochemical values occurring in each patient are summarised in Table 6 . The table represents the total experience and isolated abnormal values of no clinical significance are included. Four cimetidine-treated patients were found to have clinically significant rises in serum transaminases. One, a 61 year old man, developed an SGOT of 57 IU/I (normal < 32) and a y-GT of 182 IU/l (normal < 45) after four weeks' treatment; these changes were associated with myalgia, fever, a raised sedi- with a history of high alcohol intake, developed moderate rises in transaminases; one was known to have alcoholic cirrhosis and had abnormal liver function before treatment. The fourth patient, a 48 year old man, had an SGOT of 410 IU/l (normal < 32) on entry to the trial, but this value had returned to normal by the fourth month of treatment. There were no haematological abnormalities encountered, other than changes in haemoglobin or associated indices which could be attributed to the underlying ulcer disease. In particular, there were no significant falls in the white blood count or platelet count. No unexpected urinary abnormalities occurred.
Discussion
Allocation of patients at random to treatment with cimetidine or placebo produced two groups of patients who were similar in sex distribution, age, duration of symptoms, drinking and smoking habits. It is therefore extremely unlikely that the different clinical course of patients in the two treatment groups was due to factors other than treatment with, or without, cimetidine. The trial showed that cimetidine in a dose of 400 mg in the morning, and at bedtime over a six month period significantly reduced the rate of clinical relapse. Cimetidine also (almost certainly) prevented re-ulceration, but we cannot feel totally confident of this because some patients who were asymptomatic declined endoscopy to confirm that their ulcers were still healed. Our results are thus similar to those of Gudmand-H0yer et al. (1978) who followed their patients for one year but who had, at six months, only 1/26 (4 %) of relapses-a proportion not significantly different from what we found. Bodemar and Walan (1978) followed their patients for a year at which time six of 32 (19%) of their patients had re-ulcerated, although not all had severe symptoms. It is therefore clear that our results are not atypical in showing that maintenance therapy with cimetidine confers benefit which, however, falls short of complete immunity from further trouble. Duodenitis became more marked in patients who relapsed and re-ulcerated but the data do not help to elucidate the relationship between duodenitis, ulceration, and pain. It is interesting, however, to note that the fate of patients in the maintenance trial seems to have been partly determined by the dose of cimetidine used in the initial healing of their ulcers. Those who had 2 g/day initially did far better than those who had only 1 g/day if they were subsequently given placebo (p < 0.001). If, however, the maintenance treatment was w,th cimetidine this effect was no longer seen. This is strange because at the start of the maintenance trial all the ulcers were seen to have healed by endoscopy; we had not anticipated the possibility that some healed ulcers might be more firmly healed than others-especially since the Multicentre Trial (1979) showed no significant difference between the proportions of ulcers healing on 1 and 2 g cimetidine daily.
Cimetidine appeared to be safe: no patient was withdrawn because of unwanted effects. In contrast with the findings in short-term trials, rises in serum creatinine were no more common in cimetidine-treated patients than in those who had placebo (see, for example, Multicentre Trial, 1979) . Rises in serum uric acid and liver enzymes were likewise not significantly more common in patients on cimetidine than in those on placebo. Although four cimetidinetreated patients in our series exhibited rises in serum levels of liver enzymes, the changes were transient in two of them and were not progressive in the other two, in whom alcohol was undoubtedly an important factor.
There has been speculation that withdrawal of treatment with an H2-receptor antagonist results in severe and rapid recurrence of ulceration (Saunders and Wormsley, 1977) but, quite apart from lack of evidence for a gastrin-mediated trophic effect of cimetidine in man (Spence et al., 1978) or of a rebound in acid secretion (Bodemar and Walan, 1978) , neither our data (in the Figure) nor those of Gudmand-H0yer et al. (1978) show a relapse rate on withdrawing cimetidine which is demonstrably greater immediately after withdrawing the drug than it is a month or two later.
So, if severe and sudden relapses do in fact occur on stopping cimetidine they must be sufficiently rare not to have any visible effects on the results in two groups each of about 30 patients. 
